Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Ocean Biomedical, Inc.
Ocean Biomedical, Inc. News
Ocean Biomedical, Inc. Quantitative Score
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Ocean Biomedical, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Ocean Biomedical, Inc. Financials
Table Compare
Compare OCEA metrics with: | |||
|---|---|---|---|
Earnings & Growth | OCEA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | OCEA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | OCEA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | OCEA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Ocean Biomedical, Inc. Income
Ocean Biomedical, Inc. Balance Sheet
Ocean Biomedical, Inc. Cash Flow
Ocean Biomedical, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Ocean Biomedical, Inc. Executives
| Name | Role |
|---|---|
| Ms. Jolie G. Kahn CPA, Esq. | Chief Financial Officer |
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder & Executive Chairman of the Board |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ms. Jolie G. Kahn CPA, Esq. | Chief Financial Officer | Female | 1965 | -- |
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer | 1968 | -- | |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder & Executive Chairman of the Board | 1966 | -- |
Ocean Biomedical, Inc. Insider Trades
| Date | 14 Feb |
| Name | Poseidon Bio, LLC |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 14 Feb |
| Name | Poseidon Bio, LLC |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | |
| Shares | 18582930 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 14 Feb | Poseidon Bio, LLC | 10 percent owner | Disposed | 0 | |
| 14 Feb | Poseidon Bio, LLC | 10 percent owner | Disposed | 18582930 |